Our hypothesis is that oral L-carnosine treatment (as compared with placebo) will enhance
cognitive abilities (specifically: measures of attention, executive function, working memory,
visuospatial ability and language) in persons with bipolar disorder. Secondarily, we
hypothesize there will be secondary improvements in positive, negative and mood symptoms with
L-carnosine treatment.
We aim to test these hypotheses by conducting a randomized, placebo controlled, add on
treatment trial of L-carnosine (added to existing antipsychotic treatment) on 48 recruited
subjects with DSM IV TR bipolar disorder for a period of 12 weeks. Measures of cognition, and
psychopathology will be utilized for evaluating primary and secondary outcomes, along with
safety assessments.
Phase:
N/A
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
National Alliance for Research on Schizophrenia and Depression